NYSE:AZN - AstraZeneca Stock Price, Price Target & More

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca announced a semiannual dividend on Monday, February 5th. Investors of record on Friday, February 16th will be given a dividend of $0.95 per share on Monday, March 19th. This represents a dividend yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. View AstraZeneca's Dividend History.

AstraZeneca shares split before market open on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly minted shares were payable to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

AstraZeneca plc (NYSE:AZN) announced its quarterly earnings results on Friday, May, 18th. The company reported $0.48 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.28 by $0.20. The business had revenue of $5.18 billion for the quarter, compared to analyst estimates of $5.24 billion. AstraZeneca had a return on equity of 30.73% and a net margin of 12.61%. The company's revenue was down 4.2% on a year-over-year basis. During the same quarter last year, the company earned $0.99 earnings per share. View AstraZeneca's Earnings History.

AstraZeneca is scheduled to release their next quarterly earnings announcement on Thursday, July, 26th 2018. View Earnings Estimates for AstraZeneca.

AstraZeneca updated its FY18 earnings guidance on Friday, May, 18th. The company provided earnings per share guidance of $3.30-3.50 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.46.

17 brokers have issued twelve-month price targets for AstraZeneca's stock. Their forecasts range from $35.00 to $42.00. On average, they expect AstraZeneca's share price to reach $38.2833 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Ratings for AstraZeneca.

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 6 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

AstraZeneca saw a decrease in short interest in the month of June. As of June 29th, there was short interest totalling 7,144,897 shares, a decrease of 34.8% from the June 15th total of 10,959,514 shares. Based on an average trading volume of 3,577,564 shares, the short-interest ratio is presently 2.0 days. Approximately 0.3% of the company's stock are sold short. View AstraZeneca's Current Options Chain.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Pfizer (PFE), Novartis (NVS), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), Sanofi (SNY), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG), Allergan (AGN) and Shire (SHPG).

Press coverage about AZN stock has trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. AstraZeneca earned a media sentiment score of 0.09 on Accern's scale. They also assigned news coverage about the company an impact score of 45.32 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

AstraZeneca's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Fisher Asset Management LLC (0.52%), Hardman Johnston Global Advisors LLC (0.05%), Bank of Montreal Can (0.04%), TIAA FSB (0.02%), ZWJ Investment Counsel Inc. (0.02%) and World Asset Management Inc (0.00%). View Institutional Ownership Trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including World Asset Management Inc, Daniel Devine & Co, Fulton Bank N.A., Fox Run Management L.L.C., Hardman Johnston Global Advisors LLC, Gofen & Glossberg LLC IL, Lourd Capital LLC and Atria Investments LLC. View Insider Buying and Selling for AstraZeneca.

AZN stock was bought by a variety of institutional investors in the last quarter, including Fisher Asset Management LLC, Bank of Montreal Can, ZWJ Investment Counsel Inc., TIAA FSB, Cornerstone Wealth Management LLC, Essex Investment Management Co. LLC, BLB&B Advisors LLC and FNY Investment Advisers LLC. View Insider Buying and Selling for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $37.17.

AstraZeneca has a market capitalization of $94.55 billion and generates $22.47 billion in revenue each year. The company earns $3.00 billion in net income (profit) each year or $4.28 on an earnings per share basis. AstraZeneca employs 61,100 workers across the globe.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]